Postpartum Hemorrhage Management: Emergency Response Training

Primary PPH is classified using the four T's framework: Tone (uterine atony, 80% of cases), Trauma (genital tract injuries, 20%), Tissue (retained placenta, 10%), and Thrombosis (coagulopathy). Uterine atony occurs when the uterus fails to contract after placental separation, leaving blood vessels unclamped. Risk factors include overdistension (multiple gestations, polyhydramnios, macrosomia), rapid labor (<3 hours), prolonged labor (>12 hours), infection, dehydration, tocolytics, grand multiparity, placenta previa, and uterine malformations. Trauma from operative deliveries causes cervical, vaginal, or perineal lacerations. Retained placenta involves accessory lobes or attachment disorders (placenta accreta, increta, percreta). Coagulopathy from placental abruption, HELLP syndrome, or anticoagulant use causes oozing despite uterine contraction.

Postpartum hemorrhage (PPH) is a critical condition defined as excessive bleeding after childbirth during the first six weeks postpartum. Diagnostic criteria specify 500 ml blood loss for vaginal delivery and 1000 ml for cesarean section. PPH is classified into Primary (within 24 hours) and Secondary (24 hours to 6 weeks). The Four Ts framework explains the main causes: Tone (uterine atony, 70% of cases), Tissue (retained placenta), Trauma (lacerations, uterine rupture), and Thrombin (clotting disorders). Risk factors include uterine overdistension, placental abnormalities, instrumental delivery, and coagulopathies.

Postpartum hemorrhage is defined as blood loss ≥500ml in vaginal delivery or ≥1000ml in cesarean section. It is classified as primary (first 24 hours, most common) or secondary (24 hours to 12 weeks). Primary PPH is the leading cause of maternal mortality worldwide, occurring in 15% of births in developed countries. The 4 Ts framework explains the causes: Tonicity (uterine atony, 69%), Trauma (genital tract injuries, 20%), Tissue (retained placental tissue, 10%), and Thrombin (coagulopathies, 1%). Two-thirds occur without risk factors. Coagulopathies include pre-existing conditions (hemophilia, von Willebrand syndrome), pregnancy-related disorders (preeclampsia, HELLP syndrome), and acquired conditions (DIC, anticoagulant therapy).

Postpartum hemorrhage (PPH) is defined as blood loss causing hemodynamic instability or ≥500ml in vaginal delivery/≥1000ml in cesarean within 24 hours, and is the leading cause of maternal death worldwide. The etiology follows the 4 Ts mnemonic: Tones (uterine atony, 70%), Trauma (lacerations, 19%), Tissue (retained placental tissue, 10%), and Thrombin (coagulopathies, 1%). The critical clinical principle is that uterine atony should be the first assumption until proven otherwise. Universal prevention with 10 units IM oxytocin reduces PPH by 50%. Treatment follows a stepwise algorithm: bimanual uterine massage and IV oxytocin, followed by additional uterotronics (methylergonovine, misoprostol), intrauterine balloon tamponade, compression sutures, and finally hysterectomy if refractory.

Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide, defined as bleeding exceeding 500ml within 24 hours (primary) or 24 hours to 2 weeks (secondary). Primary PPH is classified as minor (500-1000ml) or major (>1L). The four T's mnemonic explains causes: Tone (uterine atony, 80% of cases, caused by overdistension, fatigue, or relaxants), Trauma (genital tract injuries from operative deliveries), Tissue (retained placental products, especially with accreta), and Thrombin (coagulopathies like DIC or anticoagulant use). Understanding these causes guides appropriate clinical management.

Postpartum hemorrhage assessment follows a systematic sequence: fundal assessment (position, firmness, deviation), bladder emptying (full bladder prevents uterine contraction), perineal inspection (episiotomy sutures, tears), and lochia monitoring (weighing pads, 1g blood = 1ml, hemorrhage = 500ml+ after vaginal delivery). Hypovolemic shock presents with tachycardia, confusion, cool clammy skin (peripheral vasoconstriction), and low blood pressure (late sign). Internal bleeding signs include abdominal tenderness and rigid uterus (placental abruption). High-risk patients require continuous monitoring of intake/output and bleeding. Early recognition prevents shock progression.

Hemodynamic instability is identified by altered vital signs including hypotension, tachycardia, altered respiratory rate, and fever, regardless of blood loss volume. A patient may be hemodynamically unstable even with less than 500ml blood loss if vital signs are abnormal. Hypovolemic shock is diagnosed through vital sign assessment: tachycardia (heart rate >90 bpm) is the first sign to change, followed by hypotension (systolic <90 mmHg), tachypnea (respiratory rate >30/min), altered mental status (agitation, confusion, lethargy), and decreased perfusion (cold extremities, capillary refill >2 seconds, oliguria <0.5ml/kg/hour).

Hypovolemic shock from PPH presents with specific clinical signs: Tachycardia (heart rate >100 bpm) is the earliest and most sensitive indicator. Hypotension (low blood pressure) follows. Respiratory rate increases as compensation. Temperature may rise slightly. Recognizing these signs early is critical for initiating treatment before the patient becomes critically ill.

The early signs of hypovolemic shock include tachycardia (increased pulse rate) and hypertension. The instructor explains that these are the first indicators that the body is compensating for decreased blood volume. The question specifically asks about a patient returning from abdominal surgery, where these signs would be particularly concerning.

The earliest sign of hypovolemic shock is tachycardia (increased heart rate). As shock progresses, narrowing pulse pressure develops. Pulse pressure is calculated as systolic minus diastolic blood pressure (e.g., 120/60 has a pulse pressure of 60). In shock, systolic pressure decreases while diastolic pressure may remain stable due to vasoconstriction, causing the pulse pressure to narrow progressively (from 60 to 40 to 20).

Oxytocin works on the myometrium to promote contraction. Prostaglandins work on the uterus to promote contraction. Ergometrine works on the uterus to promote contraction. Each drug has a different mechanism of action and is used in specific clinical situations.

Oxytocin binds to receptors on smooth muscle cells, activating Gq proteins that stimulate phospholipase C. This enzyme breaks down PIP2 into DAG and IP3. IP3 releases calcium from intracellular stores, while DAG activates protein kinase C. Together, these mechanisms increase intracellular calcium levels, enhancing muscle contraction to facilitate childbirth.

Uterine-acting drugs are classified as uterotonic (stimulating contractions) or tocolytic (inhibiting contractions). Uterotonic drugs act through three mechanisms: stimulating calcium entry via voltage-dependent and concentration-dependent receptors, stimulating phospholipase C and inositol triphosphate for calcium release from endoplasmic reticulum, and inhibiting adenylate cyclase to maintain calcium-calmodulin system. The four main uterotonic drugs are oxytocin, carboprost, prostaglandins, and ergometrine. Oxytocin is a nonapeptide similar to vasopressin with antidiuretic effects at low doses. Pharmacokinetics: IV infusion or IM administration, half-life 3-4 minutes, plasma stability in 20-30 minutes. Major adverse effects include uterine hyperstimulation (most feared, causing fetal hypoxia and potential death), uterine rupture, hypotension, hyponatremia, and postpartum hemorrhage. Carboprost is a thermally stable oxytocin analog with fewer side effects, indicated only for active management of third stage of labor, particularly in cesarean deliveries with spinal anesthesia.

Oxytocin release is primarily triggered by neural reflexes: suckling activates thoracic spinal segments, cervical dilation during labor activates pelvic nerve pathways, and vaginal distension also stimulates release. These stimuli activate the paraventricular and supraoptic nuclei, which release oxytocin from the posterior pituitary. Oxytocin primarily acts on smooth muscle to cause contraction: myoepithelial cells in mammary glands (milk ejection), uterine smooth muscle (labor and delivery), and male reproductive tract (ejaculation). The mechanism involves calcium mobilization and cAMP pathway activation. Progesterone antagonizes oxytocin's effects on uterine muscle, while estrogen enhances them. Oxytocin also facilitates maternal behavior and bonding, and may help mothers 'forget' childbirth pain as a neuroprotective adaptation.

Oxytocin is a peptide hormone synthesized in the hypothalamus and stored/released from the posterior pituitary that acts as a uterotonic agent by stimulating uterine contractions through GPCR receptors, increasing IP3 and calcium influx in uterine smooth muscle; it is used for labor induction, augmentation, postpartum hemorrhage control, and milk ejection, with adverse effects including uterine hyperstimulation, water intoxication, and hypotension. Tocolytic agents like beta-2 agonists (salbutamol, terbutaline, ritodrine), magnesium sulfate, nifedipine, and atosiban work by relaxing uterine smooth muscle to delay or stop preterm labor, with mechanisms involving increased cAMP, calcium channel blockade, or competitive oxytocin receptor antagonism.